Zevra Therapeutics (ZVRA) said Monday that it has completed the sale of a rare pediatric disease priority review voucher for $150 million in gross proceeds.
Zevra had received the voucher last year following US regulatory approval of its therapy for Niemann-Pick type C, Miplyffa, the commercial-stage company said.
The funds will be used to support the commercial launches of Miplyffa and Olpruva, ongoing clinical studies on celiprolol, and overall investment plans, the company said.
As of March 31, Zevra reported preliminary cash and equivalents of $68.7 million, which would rise to $217 million after accounting for post-quarter net proceeds from the sale.
Shares of the company were down more than 3.5% in recent Monday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。